Bill Sponsor
BILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 7828
117th Congress(2021-2022)
PRICED Act
Introduced
Introduced
Introduced in House on May 18, 2022
Overview
Text
Introduced in House 
May 18, 2022
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(May 18, 2022)
May 18, 2022
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 7828 (Introduced-in-House)


117th CONGRESS
2d Session
H. R. 7828


To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.

IN THE HOUSE OF REPRESENTATIVES

May 18, 2022

Ms. Schakowsky (for herself, Mr. Westerman, Mr. Khanna, Mr. Doggett, Mr. Pocan, Ms. Kaptur, Mr. García of Illinois, and Ms. DeLauro) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Price Relief, Innovation, and Competition for Essential Drugs Act” or the “PRICED Act”.

SEC. 2. Exclusivity period for brand name biological products.

(a) In general.—Section 351(k)(7)(A) of the Public Health Service Act (42 U.S.C. 262(k)(7)(A)) is amended by striking “12 years” and inserting “5 years”.

(b) Conforming changes.—Paragraphs (2)(A) and (3)(A) of section 351(m) of the Public Health Service Act (42 U.S.C. 262(m)) is amended by striking “12 years” each place it appears and inserting “5 years”.

(c) Applicability.—This Act and the amendments made by this Act apply only with respect to a biological product for which the reference product (as such term is used in section 351 of the Public Health Service Act (42 U.S.C. 262)) is licensed under subsection (a) of such section on or after the date of enactment of this Act.